國家衛生研究院 NHRI:Item 3990099045/15210

NHRI > National Institute of Infectious Diseases and Vaccinology > Chun-Hong Chen > Periodical Articles > Item 3990099045/15210

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15210

Title:	COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
Authors:	Tsai, JJ;Liu, LT;Chen, CH;Chen, LJ;Wang, SI;Wei, JCC
Contributors:	National Mosquito-Borne Diseases Control Research Center;National Institute of Infectious Diseases and Vaccinology
Abstract:	OBJECTIVES: We aimed to investigate the role of rheumatoid arthritis (RA) with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) exposure in COVID-19 outcomes. METHODS: Our study retrieved data from the US Collaborative Network in TriNetX between 1 January 2018 and 31 December 2022. We investigated b/tsDMARD use for RA: interleukin 6 inhibitor (IL-6i), Janus-associated kinase inhibitors (JAKi) or tumour necrosis factor-alpha inhibitors (TNFi, reference group). The outcomes of COVID-19 were the incidence of infection and adverse outcomes (hospitalisation, critical care services, mechanical ventilation and mortality). The HR and 95% CI of the outcomes were calculated between propensity score-matched (PSM) patients with different b/tsDMARDs. RESULTS: After PSM, 2676 JAKi vs 2676 TNFi users and 967 IL-6i vs 967 TNFi users were identified. As for COVID-19 incidence, JAKi users did not reach statistical significance (HR: 1.058, 95% CI: 0.895 to 1.250) than TNFi users. RA with JAKi users had a significant risk for hospitalisation (HR: 1.194, 95% CI: 1.003 to 1.423), mortality (HR: 1.440, 95% CI: 1.049 to 1.976) and composite adverse outcomes (HR: 1.242, 95% CI: 1.051 to 1.468) compared with TNFi users. Mortality risk tended to be significantly higher in the JAKi group without COVID-19 vaccination (HR: 1.511, 95% CI: 1.077 to 2.121). IL-6i users compared with TNFi users did not have the above findings. CONCLUSIONS: RA with JAKi users had a significant risk for hospitalisation, mortality or composite adverse outcomes, especially higher mortality among those without COVID-19 vaccination. COVID-19 vaccination should be encouraged in these target cohorts. When using JAKi for patients with RA, clinicians should be vigilant about these adverse outcomes to prevent their occurrence or detect them early for early intervention.
Date:	2023-07-21
Relation:	RMD Open. 2023 Jul 21;9:Article number e003038.
Link to:	http://dx.doi.org/10.1136/rmdopen-2023-003038
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2056-5933&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001035312100001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85165481677
Appears in Collections:	[Chun-Hong Chen] Periodical Articles [Others] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85165481677.pdf		2081Kb	Adobe PDF	111	View/Open

Loading...